{
  "meta": {
    "title": "98_Blood_Bank_Transfusion_Medicine",
    "url": "https://brainandscalpel.vercel.app/98-blood-bank-transfusion-medicine-0d7319e3.html",
    "scrapedAt": "2025-11-30T12:29:20.500Z"
  },
  "questions": [
    {
      "text": "What is the 'A blood antigen' composed of?",
      "choices": [
        {
          "id": 1,
          "text": "Galactose attached to H substance"
        },
        {
          "id": 2,
          "text": "Glucose attached to H substance"
        },
        {
          "id": 3,
          "text": "N-acetyl galactosamine attached to H substance"
        },
        {
          "id": 4,
          "text": "N-acetyl glucosamine attached to H substance"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The blood group '<strong>antigen A'</strong> is composed of <strong>N-acetyl galactosamine</strong> attached to the <strong>H substance</strong>.</p>\n<p>H substance is formed by the addition of <strong>fucose</strong> to the glycolipid or glycoprotein backbone. It is present in all blood groups, even the O group.</p>\n<p>A antigen&nbsp;= N-acetyl galactosamine + H substance&nbsp;</p>\n<p>B antigen = galactose + H substance</p>\n<p>However, in case of the<strong> Bombay phenotype,</strong>&nbsp;RBCs <strong>lack H antigen</strong>. Hence, these individuals have anti-A, anti-B, and anti-H antibodies. The only compatible blood donor is another person with the Bombay blood group.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3983",
      "difficulty": "medium"
    },
    {
      "text": "Which chromosome contains the genes that determine the A and B blood groups?",
      "choices": [
        {
          "id": 1,
          "text": "9"
        },
        {
          "id": 2,
          "text": "7"
        },
        {
          "id": 3,
          "text": "5"
        },
        {
          "id": 4,
          "text": "1"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The genes that determine the <strong>A and B blood</strong> groups are located on <strong>chromosome 9. </strong>The phenotypes are expressed in the <strong>Mendelian codominant </strong>manner.</p>\n<p><strong>Rh</strong>&nbsp;genes determining Rh blood grouping are present on <strong>chromosome 1</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3984",
      "difficulty": "medium"
    },
    {
      "text": "Individuals with a lack of which of the following blood group antigens have immunity against Plasmodium vivax?",
      "choices": [
        {
          "id": 1,
          "text": "Kell"
        },
        {
          "id": 2,
          "text": "Lewis"
        },
        {
          "id": 3,
          "text": "Kidd"
        },
        {
          "id": 4,
          "text": "Duffy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Duffy antigens&nbsp;serve as receptors for Plasmodium vivax. Hence, the <strong>absence&nbsp;</strong>of the <strong>Duffy</strong> antigen is <strong>protective</strong> against <em><strong>Plasmodium vivax</strong>.&nbsp;</em></p>\n<p>Hemoglobinopathies that are <strong>protective</strong> against <strong><em>Plasmodium&nbsp;falciparum</em></strong> include:</p>\n<ul>\n<li>Sickle cell trait</li>\n<li>Hemoglobin C&nbsp;</li>\n<li>Hemoglobin SC</li>\n<li>Hemoglobin E</li>\n<li>Hereditary persistence of fetal hemoglobin (Hb F)</li>\n<li>Alpha and beta-thalassemia</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3989",
      "difficulty": "easy"
    },
    {
      "text": "Donated blood is screened for all of the following infections except:",
      "choices": [
        {
          "id": 1,
          "text": "Kala azar"
        },
        {
          "id": 2,
          "text": "Hepatitis C"
        },
        {
          "id": 3,
          "text": "Syphilis"
        },
        {
          "id": 4,
          "text": "Malaria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Donated blood</strong> is not routinely screened for kala-azar. It&nbsp;is <strong>screened</strong> for the following <strong>infections</strong> in the blood bank:</p>\n<ul>\n<li>Human immunodeficiency virus</li>\n<li>Hepatitis B</li>\n<li>Hepatitis C</li>\n<li>Malaria</li>\n<li>Syphilis</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3992",
      "difficulty": "medium"
    },
    {
      "text": "As the medical officer at a blood bank, you are supervising the separation of blood components of donated blood. The preservative used for the packed red cells is SAG-M. Which of the following criteria must be fulfilled in order to safely transfuse this to patients?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>To be used within:</strong></td>\n</tr>\n<tr>\n<td>1.   </td>\n<td>-2° to -6 °C    </td>\n<td>    21 days</td>\n</tr>\n<tr>\n<td>2.   </td>\n<td>+2° to +6 °C  </td>\n<td>    42 days</td>\n</tr>\n<tr>\n<td>3.   </td>\n<td>-2° to -6 °C   </td>\n<td>    35 days</td>\n</tr>\n<tr>\n<td>4.   </td>\n<td>+2° to +6 °C. </td>\n<td>    48 days</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "3"
        },
        {
          "id": 4,
          "text": "4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The shelf life of packed red cells (<strong>pRBCs</strong>) in the <strong>SAG-M</strong> solution is <strong>42 days. </strong>The optimum temperature for storage of packed RBCs and whole blood collected in preservatives is <strong>+2° to +6° C</strong>. This temperature maintains the viability of the cells and prevents bacterial contamination.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Blood component </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>PRBCs</td>\n<td>+2° to +6 °C</td>\n<td>\n<p>CPD-21 days</p>\n<p>CPD-A-35 days</p>\n<p>SAG M-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Platelets</td>\n<td>+20 to +24 °C</td>\n<td>5 days</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma</td>\n<td>-30 °C or lower</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>-30 °C or lower</td>\n<td>1 years</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Blood components</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Volume     (1 unit)</strong></td>\n<td><strong>Content</strong></td>\n<td><strong>Clinical response, increase in </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>Whole blood</td>\n<td>450 ml</td>\n<td>RBCs, platelets, plasma</td>\n<td>Hb and plasma volume</td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>Packed red blood cells (PRBCs)</td>\n<td>300-350 ml</td>\n<td>RBCs</td>\n<td>\n<p>Hb by 1 g/dl</p>\n<p>Hematocrit by 3%</p>\n</td>\n<td>\n<p>1° to 6°C</p>\n</td>\n<td>\n<p>ACD/CPD-21 days, CPD-A-35 days, additive-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Random donor platelets (RDP)</td>\n<td>50-70 ml</td>\n<td>Platelets</td>\n<td>platelet count by 5000-10,000/µL</td>\n<td rowspan=\"2\">20 to 24°C</td>\n<td rowspan=\"2\">5 days</td>\n</tr>\n<tr>\n<td>Single donor apheretic platelets (SDP*)</td>\n<td>200-400 ml</td>\n<td>Platelets</td>\n<td>platelet count by 30,000/µL</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>200-250 ml</td>\n<td>Coagulation factors, protein C, protein S, anti thrombin</td>\n<td>coagulation factors by 2%</td>\n<td>-40 to -50°C</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>10-15 ml</td>\n<td>fibrinogen, factor VIII, VWF</td>\n<td>80 IU Factor VIII</td>\n<td>-30 °C</td>\n<td>1 year</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b1f01af443f48ec90792074de2e9c37x1280x1063.JPEG\" alt=\"Pearl Image\"><p>*SDP is obtained by collecting multiple units of platelets from a single donor using apheretic technology. </p>\n<p>1 SDP = 6 RDP</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1866",
      "difficulty": "medium"
    },
    {
      "text": "Packed red blood cell transfusion is started for a patient in the ward. It must be completed within:",
      "choices": [
        {
          "id": 1,
          "text": "5 hours"
        },
        {
          "id": 2,
          "text": "2 hours"
        },
        {
          "id": 3,
          "text": "3 hours"
        },
        {
          "id": 4,
          "text": "4 hours"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Transfusion of <strong>pRBCs</strong> (packed red blood cells) or whole blood should be completed <strong>within 4 hours</strong> after the commencement.&nbsp;Transfusion of platelets, fresh frozen plasma, and cryoprecipitate should be completed&nbsp;within 30 minutes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1855",
      "difficulty": "medium"
    },
    {
      "text": "Cryoprecipitate is useful for the management of patients with all of the following conditions except:",
      "choices": [
        {
          "id": 1,
          "text": "Hemophilia A"
        },
        {
          "id": 2,
          "text": "Von Willebrand disease"
        },
        {
          "id": 3,
          "text": "Hypofibrinogenemia"
        },
        {
          "id": 4,
          "text": "Christmas disease"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Cryoprecipitate</strong> does not contain factor IX. Hence, it is not useful for the management of patients with Christmas disease, which occurs due to deficiency of factor IX.</p>\n<p>Components of cryoprecipitate are:</p>\n<ul>\n<li>Factor VIII</li>\n<li>Factor XIII</li>\n<li>Fibrinogen</li>\n<li>Fibronectin</li>\n<li>Von Willebrand factor</li>\n</ul>\n<p>Therefore it can be used in patients with <strong>hemophilia A</strong>, factor XIII deficiency, <strong>hypofibrinogenemia</strong>, and <strong>von Willebrand disease</strong>.</p><hr><h3>Related Pearl: Blood components</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Volume     (1 unit)</strong></td>\n<td><strong>Content</strong></td>\n<td><strong>Clinical response, increase in </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>Whole blood</td>\n<td>450 ml</td>\n<td>RBCs, platelets, plasma</td>\n<td>Hb and plasma volume</td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>Packed red blood cells (PRBCs)</td>\n<td>300-350 ml</td>\n<td>RBCs</td>\n<td>\n<p>Hb by 1 g/dl</p>\n<p>Hematocrit by 3%</p>\n</td>\n<td>\n<p>1° to 6°C</p>\n</td>\n<td>\n<p>ACD/CPD-21 days, CPD-A-35 days, additive-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Random donor platelets (RDP)</td>\n<td>50-70 ml</td>\n<td>Platelets</td>\n<td>platelet count by 5000-10,000/µL</td>\n<td rowspan=\"2\">20 to 24°C</td>\n<td rowspan=\"2\">5 days</td>\n</tr>\n<tr>\n<td>Single donor apheretic platelets (SDP*)</td>\n<td>200-400 ml</td>\n<td>Platelets</td>\n<td>platelet count by 30,000/µL</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>200-250 ml</td>\n<td>Coagulation factors, protein C, protein S, anti thrombin</td>\n<td>coagulation factors by 2%</td>\n<td>-40 to -50°C</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>10-15 ml</td>\n<td>fibrinogen, factor VIII, VWF</td>\n<td>80 IU Factor VIII</td>\n<td>-30 °C</td>\n<td>1 year</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b1f01af443f48ec90792074de2e9c37x1280x1063.JPEG\" alt=\"Pearl Image\"><p>*SDP is obtained by collecting multiple units of platelets from a single donor using apheretic technology. </p>\n<p>1 SDP = 6 RDP</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3996",
      "difficulty": "medium"
    },
    {
      "text": "You are monitoring the falling platelet count of a 31-year-old man with dengue fever. You would recommend prophylactic platelet transfusion when the count drops below what level?",
      "choices": [
        {
          "id": 1,
          "text": "5000 platelets /μL"
        },
        {
          "id": 2,
          "text": "10000 platelets /μL"
        },
        {
          "id": 3,
          "text": "15000 platelets /μL"
        },
        {
          "id": 4,
          "text": "50000 platelets /μL"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The threshold for <strong>prophylactic</strong> <strong>platelet</strong> <strong>transfusion</strong> is <strong>10,000/&mu;L&nbsp;</strong>in order to prevent spontaneous bleeding.&nbsp;If the patient is planned for any&nbsp;<strong>invasive procedures</strong>, the target platelet level is <strong>50,000/&mu;L.</strong></p>\n<p>The shelf life of donor platelets is 5 days.&nbsp;It is stored on a special agitator at<strong>&nbsp;</strong>20-24 &deg;C.&nbsp;The&nbsp;half-life of transfused platelets&nbsp;is&nbsp;3-5 days.&nbsp;One unit of pooled platelets should be transfused within 30 minutes&nbsp;because of the risk of bacterial proliferation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3993",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following blood components does not carry the risk of transmitting cytomegalovirus infection?",
      "choices": [
        {
          "id": 1,
          "text": "Packed red blood cells"
        },
        {
          "id": 2,
          "text": "Whole blood"
        },
        {
          "id": 3,
          "text": "Fresh frozen plasma"
        },
        {
          "id": 4,
          "text": "Random donor platelets"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Fresh frozen plasma <strong>(FFP)</strong> is an <strong>acellular</strong> component and generally does not transmit viral infections.</p>\n<p><strong>Cytomegalovirus</strong> (CMV) infects &gt;50% of the general population and is transmitted by infected <strong>passenger WBCs</strong> in transfused <strong>PRBCs </strong>or<strong> platelet components.&nbsp;</strong>Cellular components that are leukocyte-reduced have a decreased risk of transmitting CMV.</p>\n<p>Infectious complications of blood transfusion include:&nbsp;</p>\n<ul>\n<li><strong>Viral infections:</strong> Hepatitis C virus, hepatitis B virus, HIV, cytomegalovirus</li>\n<li><strong>Bacterial</strong> contamination:<strong>&nbsp;</strong>sudden and fulminant onset of fever, chills, septic shock, and disseminated&nbsp;intravascular coagulation (DIC)\n<ul>\n<li>Platelet concentrates&nbsp;stored at room temperature: gram-positive&nbsp;and coagulase-negative staphylococci</li>\n<li>PRBCs: Gram-negative bacteria like&nbsp;<em>Yersinia, Pseudomonas, Serratia, Acinetobacter, </em>and <em>Escherichia</em> species</li>\n</ul>\n</li>\n<li><strong>Parasites:&nbsp;</strong>Malaria, Babesiosis, Chaga's disease</li>\n<li>Others:&nbsp;Creutzfeldt&ndash;Jakob disease (<strong>CJD</strong>)</li>\n</ul><hr><h3>Related Pearl: Blood components</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Volume     (1 unit)</strong></td>\n<td><strong>Content</strong></td>\n<td><strong>Clinical response, increase in </strong></td>\n<td><strong>Storage temperature</strong></td>\n<td><strong>Shelf-life</strong></td>\n</tr>\n<tr>\n<td>Whole blood</td>\n<td>450 ml</td>\n<td>RBCs, platelets, plasma</td>\n<td>Hb and plasma volume</td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>Packed red blood cells (PRBCs)</td>\n<td>300-350 ml</td>\n<td>RBCs</td>\n<td>\n<p>Hb by 1 g/dl</p>\n<p>Hematocrit by 3%</p>\n</td>\n<td>\n<p>1° to 6°C</p>\n</td>\n<td>\n<p>ACD/CPD-21 days, CPD-A-35 days, additive-42 days</p>\n</td>\n</tr>\n<tr>\n<td>Random donor platelets (RDP)</td>\n<td>50-70 ml</td>\n<td>Platelets</td>\n<td>platelet count by 5000-10,000/µL</td>\n<td rowspan=\"2\">20 to 24°C</td>\n<td rowspan=\"2\">5 days</td>\n</tr>\n<tr>\n<td>Single donor apheretic platelets (SDP*)</td>\n<td>200-400 ml</td>\n<td>Platelets</td>\n<td>platelet count by 30,000/µL</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>200-250 ml</td>\n<td>Coagulation factors, protein C, protein S, anti thrombin</td>\n<td>coagulation factors by 2%</td>\n<td>-40 to -50°C</td>\n<td>1 year</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>10-15 ml</td>\n<td>fibrinogen, factor VIII, VWF</td>\n<td>80 IU Factor VIII</td>\n<td>-30 °C</td>\n<td>1 year</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b1f01af443f48ec90792074de2e9c37x1280x1063.JPEG\" alt=\"Pearl Image\"><p>*SDP is obtained by collecting multiple units of platelets from a single donor using apheretic technology. </p>\n<p>1 SDP = 6 RDP</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3995",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following reactions occurs most frequently in patients undergoing blood transfusions?",
      "choices": [
        {
          "id": 1,
          "text": "Acute hemolytic transfusion reaction"
        },
        {
          "id": 2,
          "text": "Febrile non-hemolytic transfusion reaction"
        },
        {
          "id": 3,
          "text": "Transfusion-related acute lung injury"
        },
        {
          "id": 4,
          "text": "Anaphylactic reaction"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span><strong>Febrile non-hemolytic</strong> transfusion reaction (FNHTR) is the most&nbsp;frequently occurring transfusion reaction.</span></p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1902",
      "difficulty": "easy"
    },
    {
      "text": "Thirty minutes after a blood transfusion is started, a patient develops chills and severe flank pain. Her temperature is 102.4 F, SpO2 is 96%, and her blood pressure is 90/60 mm Hg. She then begins bleeding around her IV catheter site. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Anaphylactic reaction"
        },
        {
          "id": 2,
          "text": "Acute hemolytic reaction"
        },
        {
          "id": 3,
          "text": "Febrile non-hemolytic reaction"
        },
        {
          "id": 4,
          "text": "Anamnestic antibody response"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical scenario is suggestive of&nbsp;<strong>acute hemolytic</strong> transfusion reaction (AHTR).&nbsp;</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1925",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man is being evaluated in the ward for fatigue and pallor. One week ago, he had undergone a blood transfusion following a road accident. Further evaluation reveals Hb of 8.1 g/dl and positive direct Coomb's test and history of previous blood transfusion. What is the likely mechanism of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "ABO incompatibility reaction"
        },
        {
          "id": 2,
          "text": "Antibodies against donor leukocytes"
        },
        {
          "id": 3,
          "text": "Antibodies against donor IgA"
        },
        {
          "id": 4,
          "text": "Anamnestic antibody response"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This clinical scenario is suggestive of <strong>delayed hemolytic transfusion reaction</strong> (DHTR). It is due to an <strong>anamnestic antibody response.</strong> This refers to the rapid production of antibodies in the blood after exposure to an antigen to which the recipient had been previously sensitized.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3999",
      "difficulty": "hard"
    },
    {
      "text": "Which among the following options is the most common cause of death in patients undergoing blood transfusions?",
      "choices": [
        {
          "id": 1,
          "text": "Febrile non-hemolytic transfusion reaction"
        },
        {
          "id": 2,
          "text": "Acute hemolytic transfusion reaction"
        },
        {
          "id": 3,
          "text": "Delayed hemolytic transfusion reaction"
        },
        {
          "id": 4,
          "text": "Transfusion-related acute lung injury"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Transfusion-related acute lung injury (<strong>TRALI</strong>) is the most common cause of <strong>transfusion-related fatalities</strong>.</p>\n<p>TRALI is due to the presence of <strong>anti-HLA class II antibodies&nbsp;</strong>in the donor plasma. These antibodies&nbsp;bind recipient leukocytes, which aggregate in the pulmonary vasculature and release mediators that increase capillary permeability.&nbsp;<strong>Multiparous women</strong> are frequently&nbsp;implicated donors. Recipients with a history of liver disease, smoking, alcohol use are at a higher risk.</p>\n<p>It&nbsp;occurs within <strong>6 hours</strong> of transfusion and results in <strong>hypoxia</strong> and signs of non-cardiogenic <strong>pulmonary edema</strong> with bilateral interstitial infiltrates on chest X-ray. It is managed with supportive care.</p>\n<p>&nbsp;</p>\n<p>Note: According to the latest edition of Harrison's, transfusion associated circulatory overload (<strong>TACO</strong>) is the leading cause of death followed by TRALI.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1931",
      "difficulty": "easy"
    },
    {
      "text": "Following a normal vaginal delivery, a 30-year-old woman develops severe postpartum hemorrhage. Over the next 24 hours, she undergoes transfusion of 11 units of pRBCs. She is at risk for all of the following complications except:",
      "choices": [
        {
          "id": 1,
          "text": "Metabolic alkalosis"
        },
        {
          "id": 2,
          "text": "Hypercalcemia"
        },
        {
          "id": 3,
          "text": "Hyperkalemia"
        },
        {
          "id": 4,
          "text": "Hypothermia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Massive transfusion</strong> is defined as transfusion of at least <strong>10 units</strong> of red cells in <strong>24 hours</strong> or 4 units in 1 hour.&nbsp;<strong>Hypocalcemia,</strong> not hypercalcemia, is a complication of massive blood transfusion.</p>\n<p>Blood is anticoagulated with sodium citrate and citric acid. It binds to calcium and magnesium, leading to low levels of both. Citrate is also metabolized to&nbsp;bicarbonate, causing&nbsp;<strong>metabolic alkalosis.</strong></p><hr><h3>Related Pearl: Complications of a Massive Transfusion</h3><p><strong>Massive transfusion (MT)</strong>&nbsp;is defined as the replacement by transfusion of <strong>10 units of pRBCs</strong>&nbsp;in <strong>24 hours&nbsp;</strong>or more than <strong>4 units of pRBCs</strong> in <strong>one hour</strong>.</p>\n<p>Complications from massive transfusion include:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Complication</strong></td>\n<td><strong>Mechanism</strong></td>\n</tr>\n<tr>\n<td>Hypothermia</td>\n<td>As blood products are normally stored between 1&deg;C and 6&deg;C</td>\n</tr>\n<tr>\n<td>Coagulopathy</td>\n<td>\n<p>MT with PRBCs alone causes a <strong>dilutional coagulopathy&nbsp;</strong>(vs&nbsp;consumptive coagulopathy caused by&nbsp;massive hemorrhage)</p>\n<p>Can be prevented by starting early transfusion of FFP, platelets, pRBCs in a <strong>1:1:1 ratio</strong></p>\n</td>\n</tr>\n<tr>\n<td>Acidosis/ Alkalosis</td>\n<td>\n<p>Mild acidosis - increased CO2 levels in stored blood by 21-35 days</p>\n<p>Metabolic alkalosis -&nbsp;citrate gets metabolized to bicarbonate</p>\n<p>Metabolic acidosis - due to tissue hypoperfusion</p>\n</td>\n</tr>\n<tr>\n<td>Hyperkalemia/ Hypokalemia</td>\n<td>\n<p>Initially - Hyperkalemia, as stored blood has high K+ levels due to inactivated Na/K/ATPase pump</p>\n<p>Later - Hypokalemia, due to intracellular potassium uptake and metabolic alkalosis</p>\n</td>\n</tr>\n<tr>\n<td>Hypocalcemia</td>\n<td>Stored blood is anticoagulated with citrate, which binds calcium.</td>\n</tr>\n<tr>\n<td>Hypomagnesemia</td>\n<td>Infusion of large volumes of magnesium-poor fluids and&nbsp;binding of magnesium to citrate</td>\n</tr>\n<tr>\n<td>Impaired O2-carrying capacity of hemoglobin</td>\n<td>Decreased 2, 3 DPG</td>\n</tr>\n<tr>\n<td>Volume overload</td>\n<td>Due to massive transfusion</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1928",
      "difficulty": "medium"
    },
    {
      "text": "A patient with thalassemia has a history of multiple blood transfusions, iron overload, and cardiac arrhythmia. She has now come for blood transfusion and during the process, complains of backache and looks very anxious. What would you do next?",
      "choices": [
        {
          "id": 1,
          "text": "Stop the blood transfusion"
        },
        {
          "id": 2,
          "text": "Continue the transfusion but do an ECG"
        },
        {
          "id": 3,
          "text": "Stop the transfusion. Wait for patient to become normal and then start it again"
        },
        {
          "id": 4,
          "text": "Do clerical check and get ECG"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The patient&nbsp;is being<strong> transfused blood</strong> and has complaints of backache<strong>, </strong>this is suggestive of an <strong>acute hemolytic transfusion reaction. </strong></p>\n<p>The first step is to stop transfusion immediately and then collect<strong> blood samples</strong> for testing.</p>\n<p>Acute hemolytic transfusion reactions typically occur within the <strong>first 24 hours </strong>following a blood transfusion, primarily due to <strong>ABO incompatibility</strong>.</p>\n<p>It presents with symptoms such as hypotension, tachypnea, tachycardia, fever (1-2&deg;C increase in temperature), chills, chest and back pain, hemoglobinuria, and hemoglobinemia. In severe cases, disseminated intravascular coagulation (DIC), acute renal failure, shock, and death can occur.</p>\n<p>Management of immune-mediated acute hemolytic transfusion reactions is to provide supportive care, administer vigorous hydration with isotonic saline and use diuretics to maintain urine output.</p><hr><h3>Related Pearl: Blood Transfusion Reactions</h3><table>\n<tbody>\n<tr>\n<td colspan=\"4\"><span><strong>Immunological Transfusion Reactions</strong>&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Reaction<br /></strong></span><span><strong>(Onset)</strong></span></p>\n</td>\n<td><span><strong>Mechanism</strong></span></td>\n<td><span><strong>Presentation</strong></span></td>\n<td><span><strong>Management</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Anaphylactic transfusion reaction</strong></span></p>\n<p><span>(Seconds-minutes)</span></p>\n</td>\n<td>\n<p><span>Common in<strong> IgA</strong> deficient recipients&nbsp;</span></p>\n</td>\n<td>\n<p><span>Shock, respiratory distress, angioedema</span></p>\n</td>\n<td>\n<p>Stop transfusion immediately, give epinephrine</p>\n<p><span>Prevention &ndash; using IgA deficient plasma and washed cellular blood components</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Allergic/ Urticarial transfusion reaction</strong></span></p>\n<p><span>(Within 2-3 hours)</span></p>\n</td>\n<td>\n<p><span>Recipient <strong>IgE</strong> against donor components causing mast cell activation</span></p>\n</td>\n<td>\n<p><span>Urticaria, flushing, pruritus</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Febrile non-hemolytic transfusion reaction</strong></span></p>\n<p><span>(within&nbsp;</span><span>6h)</span></p>\n<p>&nbsp;</p>\n<p><span><span>(Most common complication of blood transfusion)</span></span></p>\n</td>\n<td>\n<p><span>Antibodies against donor WBC and <strong>HLA</strong> antigens (sensitization)</span></p>\n<p><span>Cytokine accumulation during blood storage</span></p>\n<p><span>More common in multipally transfused patients and multiparous women</span></p>\n</td>\n<td>\n<p><span>Fever and chills sometimes with mild dyspnoea</span></p>\n</td>\n<td>\n<p><span>Antihistamines and antipyretics</span></p>\n<p><span>Transfusion can be stopped if symptoms are severe</span></p>\n<p>Prevention: Leukoreduced products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Transfusion-related acute lung injury (TRALI)</strong></span></p>\n<p><span>(1-6 hours)</span></p>\n</td>\n<td>\n<p><span>Anti-HLA type 2 antibodies in donor plasma bind recipient WBCs, increase capillary permeability</span></p>\n</td>\n<td>\n<p><span>Hypoxia, non-cardiogenic pulmonary edema</span></p>\n<p><span>CXR: Bilateral interstitial infiltrates</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately</span></p>\n<p><span>Supportive care</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Acute hemolytic transfusion reaction</strong></span></p>\n<p><span>(during transfusion to within 24h)</span></p>\n</td>\n<td>\n<p><span>ABO incompatibility</span></p>\n<p><span>(Type 2 hypersensitivity)</span></p>\n<p><span>Pre-existing high affinity IgM antibodies rapidly induce complement mediated lysis, intra-vascular hemolysis, and hemoglobinuria</span></p>\n</td>\n<td>\n<p><span>Fever, chills, flank/back pain</span></p>\n<p><span>Sense of impending doom</span></p>\n<p><span>Hemoglobinuria</span></p>\n<p><span>DIC, Renal failure</span></p>\n<p><span>Coomb&rsquo;s test positive, pink plasma</span></p>\n</td>\n<td>\n<p><span>Stop transfusion immediately, aggressively manage with IV fluids</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Delayed hemolytic transfusion reaction</strong></span></p>\n<p><span>occurs after 24 hours ( usually 2 weeks )</span></p>\n</td>\n<td>\n<p><span>Recipients have prior exposure to RBC antigens. </span><span>After the transfusion, anamnestic response results in antibody production</span></p>\n<p><span>Typically caused by IgG antibodies to foreign protein antigens and are associated with laboratory features of hemolysis.</span></p>\n</td>\n<td>\n<p><span>Mild fever, hemolytic anemia</span></p>\n<p><span>Coomb&rsquo;s test positive</span></p>\n<p><span>Screening for new antibodies positive</span></p>\n</td>\n<td>\n<p><span>Supportive care</span></p>\n<p><span>Additional transfusions if needed</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span><strong>Non-immune</strong> mediated transfusion reactions are as follows:</span></p>\n<ul>\n<li><span>Transfusion-associated circulatory overload (TACO)</span></li>\n<li><span>Hypothermia</span></li>\n<li><span>Electrolyte abnormality- hyperkalemia, hypocalcemia</span></li>\n<li><span>Iron overload</span></li>\n<li><span>Transient hypotension</span></li>\n<li><span>Immunomodulation</span></li>\n<li><span>Blood-borne infections&nbsp;</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7039",
      "difficulty": "medium"
    },
    {
      "text": "A patient of hemophilia received multiple blood transfusions. Which of the following metabolic abnormalities can be seen in a patient?",
      "choices": [
        {
          "id": 1,
          "text": "Metabolic alkalosis"
        },
        {
          "id": 2,
          "text": "Respiratory alkalosis"
        },
        {
          "id": 3,
          "text": "Metabolic acidosis"
        },
        {
          "id": 4,
          "text": "Respiratory acidosis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Among the given options, the <strong>metabolic abnormality</strong> seen in a patient who has received <strong>multiple blood transfusions</strong> is <strong>metabolic alkalosis</strong>.</p>\n<p>This is because the <strong>excess sodium citrate</strong> (anticoagulant) in the transfused blood gets <strong>converted to bicarbonate</strong> leading to <strong>metabolic alkalosis</strong>. Each mmol of citrate generates 3 mEq of bicarbonate (a total of 23 mEq of bicarbonate due to each unit of blood).</p>\n<p>Metabolic acidosis can also be seen in multiple blood transfusions as citrate is acidic, but <strong>metabolic alkalosis</strong> is <strong>more common</strong>.</p><hr><h3>Related Pearl: Complications of a Massive Transfusion</h3><p><strong>Massive transfusion (MT)</strong>&nbsp;is defined as the replacement by transfusion of <strong>10 units of pRBCs</strong>&nbsp;in <strong>24 hours&nbsp;</strong>or more than <strong>4 units of pRBCs</strong> in <strong>one hour</strong>.</p>\n<p>Complications from massive transfusion include:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Complication</strong></td>\n<td><strong>Mechanism</strong></td>\n</tr>\n<tr>\n<td>Hypothermia</td>\n<td>As blood products are normally stored between 1&deg;C and 6&deg;C</td>\n</tr>\n<tr>\n<td>Coagulopathy</td>\n<td>\n<p>MT with PRBCs alone causes a <strong>dilutional coagulopathy&nbsp;</strong>(vs&nbsp;consumptive coagulopathy caused by&nbsp;massive hemorrhage)</p>\n<p>Can be prevented by starting early transfusion of FFP, platelets, pRBCs in a <strong>1:1:1 ratio</strong></p>\n</td>\n</tr>\n<tr>\n<td>Acidosis/ Alkalosis</td>\n<td>\n<p>Mild acidosis - increased CO2 levels in stored blood by 21-35 days</p>\n<p>Metabolic alkalosis -&nbsp;citrate gets metabolized to bicarbonate</p>\n<p>Metabolic acidosis - due to tissue hypoperfusion</p>\n</td>\n</tr>\n<tr>\n<td>Hyperkalemia/ Hypokalemia</td>\n<td>\n<p>Initially - Hyperkalemia, as stored blood has high K+ levels due to inactivated Na/K/ATPase pump</p>\n<p>Later - Hypokalemia, due to intracellular potassium uptake and metabolic alkalosis</p>\n</td>\n</tr>\n<tr>\n<td>Hypocalcemia</td>\n<td>Stored blood is anticoagulated with citrate, which binds calcium.</td>\n</tr>\n<tr>\n<td>Hypomagnesemia</td>\n<td>Infusion of large volumes of magnesium-poor fluids and&nbsp;binding of magnesium to citrate</td>\n</tr>\n<tr>\n<td>Impaired O2-carrying capacity of hemoglobin</td>\n<td>Decreased 2, 3 DPG</td>\n</tr>\n<tr>\n<td>Volume overload</td>\n<td>Due to massive transfusion</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0224",
      "difficulty": "medium"
    }
  ]
}